Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Tumor adaptation and resistance to RAF inhibitors

Class:Id	LiteratureReference:6790435
_displayName	Tumor adaptation and resistance to RAF inhibitors
_timestamp	2015-08-10 14:41:19
author	[Person:6790434] Lito, Piro [Person:1218832] Rosen, N [Person:6790436] Solit, David B
created	[InstanceEdit:6790433] Rothfels, Karen, 2015-08-10
journal	Nat. Med.
pages	1401-9
pubMedIdentifier	24202393
title	Tumor adaptation and resistance to RAF inhibitors
volume	19
year	2013
(literatureReference)	[Reaction:6802908] RAS mutants bind inactive RAF [Homo sapiens] [Reaction:6802912] High kinase activity BRAF mutants bind MAP2Ks and MAPKs [Homo sapiens] [Reaction:6802924] RAF is phosphorylated downstream of oncogenic RAS [Homo sapiens] [Reaction:6802930] Dimerization of BRAF V600E splice variants contributes to BRAF inhibitor resistance [Homo sapiens] [Pathway:6802946] Signaling by moderate kinase activity BRAF mutants [Homo sapiens] [Pathway:6802948] Signaling by high-kinase activity BRAF mutants [Homo sapiens] [Pathway:6802957] Oncogenic MAPK signaling [Homo sapiens] [BlackBoxEvent:6803240] Homo- or heterodimerization of RAF downstream of mutant RAS [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by Tumor adaptation and resistance to RAF inhibitors (6790435)